LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.45 -4.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.44

Max

1.53

Põhinäitajad
By Trading Economics
Sissetulek	13M -43M
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	17M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+75.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-6.7M 98M
Eelmine avamishind	6.06
Eelmine sulgemishind	1.45

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. sept 2025, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17. sept 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17. sept 2025, 21:59 UTC

Tulu

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17. sept 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17. sept 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17. sept 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17. sept 2025, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17. sept 2025, 21:00 UTC

Tulu

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17. sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. sept 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17. sept 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17. sept 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17. sept 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17. sept 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17. sept 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17. sept 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17. sept 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17. sept 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17. sept 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17. sept 2025, 16:51 UTC

Tulu

Correct: Exor 1H Net Loss -EUR624M

17. sept 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17. sept 2025, 16:25 UTC

Tulu

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17. sept 2025, 16:23 UTC

Tulu

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

75.16% tõus

12 kuu keskmine prognoos

Keskmine 2.68 USD 75.16%

Kõrge 4 USD

Madal 1.7 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.